PCM
NGM

Penserra Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Penserra Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,765
Closed -$37K – 1596
2021
Q3 		$37K Buy
1,765
+10
+0.6% +$220 ﹤0.01% 1141
2021
Q2 		$34K Buy
1,755
+90
+5% +$2.11K ﹤0.01% 1079
2021
Q1 		$48K Buy
1,665
+80
+5% +$2.24K ﹤0.01% 820
2020
Q4 		$48K Buy
1,585
+997
+170% +$21.8K ﹤0.01% 695
2020
Q3 		$9K Buy
+588
New +$10.7K ﹤0.01% 829

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Penserra Capital Management's NGM Position: Q4 2021 in Review

Penserra Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2021, closing a stake of 1,765 shares — an estimated $37K sold.

Penserra Capital Management first reported a position in NGM in Q3 2020 and held it in 5 quarters. The position peaked at $48K in Q1 2021. 119 funds tracked by Wall St. Rank hold NGM as of Q4 2021.

  • Penserra Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,765 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $37K.
  • Penserra Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $48K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.